India's global export share in pharmaceuticals and Active Pharmaceutical Ingredients (APIs) stands at a modest 2.8 per cent, even as the country ranks among the world's largest suppliers of generic medicines, according to a NITI Aayog report released on Tuesday, 23 June. The report highlights significant headroom for expansion as global demand for biologics, speciality therapeutics, and advanced medicines accelerates.

Scale of the Global Opportunity

Global pharmaceutical and API import demand is valued at approximately $1.3 trillion for 2025, including $261.2 billion in APIs alone. India's pharmaceutical and API exports stood at nearly $35.8 billion — a substantial figure, but one that reflects a disproportionately small slice of a vast and growing market.

The sector contributes over 1.7 per cent to India's GDP, accounts for 7.2 per cent of manufacturing Gross Value Added (GVA), and supports approximately 2.7 million livelihoods across the value chain.

Where India Leads — and Where It Lags

India's comparative advantage remains concentrated in formulations — particularly retail medicaments and generic drugs — where it holds strong competitive positions even in tightly regulated markets such as the United States and Europe. The country is widely recognised as the world's leading supplier of generic medicines and a critical provider of vaccines and essential therapeutics.

However, the global pharmaceutical landscape has increasingly pivoted toward high-value segments: biologics, vaccines, immunologicals, and advanced therapeutics. In these segments, India's export presence remains limited, the report noted — a structural gap that constrains both revenue growth and strategic influence in global health supply chains.

What NITI Aayog Said

NITI Aayog Vice Chairman Ashok Kumar Lahiri acknowledged both the sector's strengths and its vulnerabilities. 'India is the world's leading supplier of generic medicines and a major provider of vaccines and essential therapeutics, making an important contribution to global health security. However, changing demand patterns, tighter regulatory standards, and evolving supply chains are reshaping the industry,' he said.

Lahiri added that expanding into high-value segments and leveraging the ongoing diversification of global supply chains present significant opportunities to strengthen India's position as a global pharmaceutical and innovation hub. The report, published for Q4 FY26, described the pharmaceutical sector as 'a strategic pillar of the economy, supported by a strong manufacturing base, global competitiveness in generic medicines, and growing integration into international healthcare supply chains.'

Broader Trade Context

The pharma findings come in the context of India's expanding overall trade footprint. During FY 2025-26, India's total merchandise and services trade reached approximately $1.84 trillion, reflecting deepening integration with global markets and a more sophisticated export basket.

Lahiri stressed that 'enhancing export competitiveness, raising domestic value addition, and deepening participation in value chains will remain critical to sustaining high and inclusive growth' as India pursues its long-term development goals.

What Needs to Change

The report implicitly calls for a strategic reorientation — from volume-driven generics toward innovation-led, high-margin segments. This comes amid a broader global push to de-risk pharmaceutical supply chains following disruptions exposed during the COVID-19 pandemic, when India's role as a vaccine supplier earned it significant geopolitical capital. Notably, translating that goodwill into durable market share in biologics and speciality drugs will require sustained investment in R&D, regulatory harmonisation, and domestic API self-sufficiency. The next phase of India's pharma growth story, the report suggests, hinges on whether the industry can make that leap.